A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia

PHASE3TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

October 29, 2020

Study Completion Date

January 20, 2021

Conditions

Chronic Phase Chronic Myeloid Leukemia

Interventions

DRUG

Ponatinib 30 mg QD

Ponatinib 30 mg, taken orally once daily.

DRUG

Ponatinib 15 mg QD

Ponatinib 15 mg, taken orally once daily.

DRUG

Nilotinib 400 mg BID

Nilotinib 400 mg, taken orally twice daily.

Trial Locations (1)

Cliniques Universitaire Saint-Luc (Site 058), Brussels